← Back to Search

Other

VCTX211 for Type 1 Diabetes

Phase 1 & 2

Recruiting

Research Sponsored by CRISPR Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from implantation up to 12 months post implantation

Awards & highlights

Study Summary

This trial looks at the safety and effectiveness of VCTX211 to treat Type 1 diabetes.

Who is the study for?

This trial is for people who have had Type 1 Diabetes (T1D) for at least 5 years and are on a stable diabetes treatment plan. They can't join if they've used immunosuppressants recently, had certain organ transplants, other types of diabetes, gene therapy treatments, or frequent severe unexplained drops in blood sugar.Check my eligibility

What is being tested?

The study is testing VCTX211, a new combination product to see how safe and effective it is for treating T1D. It's an early-stage trial where everyone gets the same treatment without any placebos or comparison groups.See study design

What are the potential side effects?

While specific side effects aren't listed here, typical risks may include immune system reactions due to the nature of autoimmune disease treatments like inflammation or allergic responses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from implantation up to 12 months post implantation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from implantation up to 12 months post implantation

This trial's timeline: 3 weeks for screening, Varies for treatment, and from implantation up to 12 months post implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

C-Peptide

Incidence of adverse events with causality related to VCTX211 units, the surgical procedures and/or medical interventions required to implant and explant the VCTX211 units.

Secondary outcome measures

Insulin

Body Weight Changes

Hypoglycemia

+7 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: VCTX211 unitExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor

8 Previous Clinical Trials

852 Total Patients Enrolled

ViaCyteIndustry Sponsor

6 Previous Clinical Trials

160 Total Patients Enrolled

Sandeep Soni, MDStudy DirectorCRISPR Therapeutics

5 Previous Clinical Trials

33 Total Patients Enrolled

Media Library

VCTX211 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05565248 — Phase 1 & 2

Diabetes Research Study Groups: VCTX211 unit

Diabetes Clinical Trial 2023: VCTX211 Highlights & Side Effects. Trial Name: NCT05565248 — Phase 1 & 2

VCTX211 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05565248 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the research mandate a minimum age for enrollment?

"This clinical trial is open to individuals between 18 and 65 years of age."

Answered by AI

Is the recruiting process still open for this research experiment?

"Affirmative. Per the information available on clinicaltrials.gov, this medical trial is still looking for participants and was recently updated on March 13th 2023. This study calls for 40 individuals to be enrolled at two different centres."

Answered by AI

Who is eligible to join this medical trial?

"This research project is looking for 40 people aged 18 to 65 who have been diagnosed with a metabolic condition and have had type 1 diabetes (T1D) for at least 5 years. Additionally, participants must have maintained a stable regimen related to their illness in the 3 months prior to being accepted into the study."

Answered by AI

How many individuals have been accepted into this medical trial thus far?

"Affirmative. According to clinicaltrials.gov, this medical trial began recruitment on the 20th of January in 2022 and was recently refreshed on 13th March 2022. Presently, 40 individuals must be enrolled across two separate sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

2023. "An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05565248.

All > Pandas > Type 1 Diabetes